NeoTherma Oncology
Wichita
About NeoTherma Oncology
NeoTherma Oncology is developing VectRx™, a noninvasive thermal oncology therapeutic device system for treatment of a wide range of cancers in addition to Pancreatic Ductal Adenocarcinoma, the eighth most common cancer but the fourth leading cause of cancer death in the United States. VectRx is designed to ‘plug and play’ with the global installed base of MRI scanners to deliver non-invasive, image-guided adjuvant thermal oncology therapy, which is expected to increase life expectancy and improve quality of life of patients who receive it in addition to standard-of-care radio-, chemo- and immuno- therapies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2018)
- Website: neothermaoncology.com
- Phone: 512.461.0197
Industries & Categories
Biotechnology, Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/neotherma-oncology-118947 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.